Lipid lowering therapy Videos

In this video, Prof. Christopher P. Cannon presents an infographic on treatment persistence and non-adherence in Atherosclerotic Cardiovascular Disease.

Prof. Christopher P. Cannon

First published: July 16, 2025  

In this video, Prof. Deepak L. Bhatt presents an infographic on the role of eicosanoids in atherosclerosis with a focus on IPE as therapeutic option for CVD.

Prof. Deepak L. Bhatt

First published: May 29, 2025  

Check out our latest animated video to learn more about the one-year follow-up of the SANTORINI study.

First published: March 13, 2025  

In this video, Prof. Maciej Banach discusses the 2024 recommendations on the optimal use of LLT in established ASCVD and following ACS.

First published: March 4, 2025  

In this video, Prof. Christopher Cannon and Prof. Maciej Banach discuss the current status of lipid lowering therapy with a focus on combination therapy.

First published: March 4, 2025  

In this video, Prof Stephen Nicholls discusses the future of ASCVD and Lipidology in 2025.

First published: February 24, 2025  

Welcome to our latest video! This video explores the emerging role of inclisiran, a small interfering RNA (siRNA) therapeutic that targets PCSK9, in the management of atherosclerotic cardiovascular disease. The summary delves into the mechanism of actions of inclisiran, its safety profile, results from clinical trials and the latest data presented at the ESC congress.

First published: January 13, 2025  

In this video, Prof. Deepak L. Bhatt presents an infographic on Proprotein Convertase Subtilisin/Kexin Type 9 in Cholesterol Homeostasis, Inflammation, and Thrombosis Associated with Cardiovascular Diseases – an overview of molecular functions and therapeutic strategies.

Prof. Deepak L. Bhatt

First published: September 10, 2024  

In this video, Prof. Lale Tokgozoglu of Hacettepe University, former president of the European Atherosclerosis Society, discusses the structure, function, and genetics of Lp(a) and highlights the clinical implications of elevated Lp(a) levels. Using evidence from contemporary clinical studies, Prof. Tokgozoglu shares insights into approaches for lowering Lp(a) levels. Finally, challenges in the comprehensive understanding of the physiological and clinical implications of Lp(a) are discussed. Learning outcome – High levels of lipoprotein(a) increase the chances of experiencing heart attack, stroke, and aortic stenosis.

Prof. S. Lale Tokgözoğlu

First published: March 11, 2024  

In this video, Prof. Stephen Nicholls provides a comprehensive overview of our infographic on lipid measurements and their clinical implications, serving as a helpful resource for healthcare professionals involved in managing cardiovascular disease. Covering atherogenic dyslipidemia, lipid profile components, advanced tests, and genetic considerations, Prof. Nicholls emphasizes individualized approaches to interpreting lipid parameters based on patient demographics and risk levels. This aims to guide clinicians in optimizing lipid-lowering therapy for cardiovascular risk prevention.

First published: March 6, 2024  

Watch part one of the ESC Highlights Video. In this video Prof. Lale Tokgözoğlu summarizes some of the exciting findings that were presented in ESC 2022.

Prof. Christopher P. Cannon and Prof. S. Lale Tokgözoğlu

First published: November 1, 2022  

Watch part two of the ESC Highlights Video wherein Prof. Christopher Cannon and Prof. Lale Tokgözoğlu discuss results of some exciting trials highlighting the significance of Lp(a), PCSK9 inhibitors, patient adherence and compliance.

Prof. Christopher P. Cannon and Prof. S. Lale Tokgözoğlu

First published: November 1, 2022